To weigh the contribution of these modules to clinical aggressiveness in vivo, we analyzed the expression of a panel of 239 genes, including 209 RUNX2-direct targets belonging to 11 out of 12 identified gene modules (Fig. S7A) in wo retrospective independent cohorts of TC and BC from our institution. Here, RUNX2 is linked to breast cancer.